The antiproliferative effect of C2-ceramide on lung cancer cells through apoptosis by inhibiting Akt and NFkappaB
By: Lin, I-Ling, Chou, Han-Lin, Lee, Jin-Ching, Chen, Feng-Wei, Fong, Yao, Chang, Wei-Chiao, Huang, Hurng Wern, Wu, Chang-Yi, Chang, Wen-Tsan, Wang, Hui-Min, Chiu, Chien-Chih
BioMed Central Ltd
2014-01-06; doi: 10.1186/1475-2867-14-1
BioMed Central Ltd
2014-01-06; doi: 10.1186/1475-2867-14-1
Abstract
The anticancer effects of ceramide have been reported in many types of cancers but less in lung cancer. In this study, we used C2-ceramide to further investigate its possible anticancer effects and mechanisms on non-small cell lung cancer (NSCLC) H1299 cells. The result of cell proliferation in terms of trypan blue assay showed high dose of C2-ceramide inhibited cell survival after 24 h treatment. The flow cytometry-based assays indicated the effect of apoptosis, chromatin condensation, and G1 arrest in terms of Annexin V/propidium iodide (PI), DAPI, and PI stainings, respectively. Moreover, the decreased protein level of p-Akt, p-NFkappaB, survivin and cyclin A2 were detected by Western blot assay. Taken together, these results indicated the antiproliferative effect of C2-ceramide is majorly responsible for cell apoptosis in lung cancer H1299 cells.
The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.
